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The development and evaluation of effective therapies and vac-
cines for the hepatitis C virus (HCV) and the study of its interac-
tions with the mammalian host have been hindered for a long
time by the absence of suitable small animal models. Due to the
narrow host tropism of HCV, the development of mice that can
be robustly engrafted with human hepatocytes was a major
breakthrough since they recapitulate the complete HCV life cycle.
This model has been useful to investigatemany aspects of the HCV
life cycle, including antiviral interventions. However, studies of
cellular immunity, immunopathogenesis and resulting liver dis-
eases have been hampered by the lack of a small animal model
with a functional immune system. In this review, we summarize
the evolution of in vivo models for the study of HCV.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction to experimental models for HCV research
A breakthrough discovery that guided the development of HCV
research tools was the cloning of the HCV genome 25 years ago
[1]. However, early attempts to initiate viral replication in vitro
or in various small animal models failed, restricting functional
studies to humans and chimpanzees [2–5]. This remained a major
roadblock for HCV research until the HCV replicon system became
available in 1999 [6,7]. In this system, efﬁcient viral replication
was reached in hepatoma cells, transfectedwith sub-genomes that
were comprised of a selectable marker, linked to the HCV non-
structural region NS3 up to NS5B and the 30 UTR, respectively
under the control of the 50 HCV-internal ribosome entry site (IRES)
and the IRES of the encephalomyocarditis virus (EMCV). This
system allowed the in vitro study of HCV RNA replication and the
evaluationof novel antiviral compounds, but also led tokeydiscov-
eries such as NS3/4A-mediated innate immunity interference [8,9]Journal of Hepatology 20
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E-mail address: Philip.meuleman@ugent.be (P. Meuleman).and growth factor signalling induction [10]. In parallel, several
models to study HCV binding and entry in vitro were developed,
such as virus-like particles (VLP), produced in a baculovirus system
[11] and retroviral particles, pseudotyped with HCV envelope gly-
coproteins (HCVpp) [12,13]. In 2005, a full-length isolate of HCV
(JFH1) [14,15] and the intragenotypic chimeric J6-JFH1 [16] were
described that, besides RNA replication and viral entry, also sup-
ported infectious viral particle production in vitro (HCVcc).
Together with the (sub)genomic replicon, this HCVcc system has
been the working horse for screening and identiﬁcation of new
antiviral drugs [17]. Since only recently alternative full-length iso-
lates have been described that efﬁciently propagate in cell culture
[18–22], this system has long been restricted to one speciﬁc viral
isolate, designated JFH1, and intra- or inter-genotypic chimeric
derivatives thereof [23]. In addition, hepatoma cells that support
robust replication of HCVcc have characteristics that differ signif-
icantly from those of primary human hepatocytes, e.g., continuous
proliferation, impaired innate immunity and reduced metabolic
activity [24,25]. Indeed, the in vivo target cell of HCV, the hepato-
cyte, is characterized by a highly-polarized morphology and
resides in a complex liver architecture [26]. Consequently, studies
on virus–host interactions have been hampered by limited in vivo
and ex vivo models that more closely mimic the natural infection
and environment of the liver. Primary HCV isolates show no, or
only poor ability to replicate in tissue culture and the use of pri-
mary hepatocytes in culture is complicated by rapid loss of differ-
entiation, low-level viral replication and poor reproducibility
[27,28]. Some advances have been made in this area by the use
of primary human hepatocytes in combinationwith a highly repli-
cative JFH1-variant [28], ﬂuorescence-based reporter systems
in co-cultures of primary human hepatocytes with supportive
stroma [29], primary human foetal liver cultures [30,31], a human
liver slice model [32] and more recently with induced pluripotent
stem cell derived hepatocyte-like cells [33–35].
Although these cell culture models have proven very useful to
study different aspects of the HCV life cycle, their lack of physio-
logical cell-cell interactions has greatly limited the generalizabil-
ity of these ﬁndings. One example of such a discrepancy was the
increased HCV blocking efﬁcacy of an anti-SR-BI entry inhibitor
in vivo compared to results generated in cell culture studies
[36]. Therefore, in vivo studies that more closely mimic the natu-
ral situation in humans are essential. A milestone discovery,
enabling such in vivo HCV studies, was the generation of mice
that can be robustly engrafted with human hepatocytes [37].14 vol. 61 j S26–S33
B
a
si
c
JOURNAL OF HEPATOLOGYKey Points
• The chimpanzee has been a valuable model to study 
HCV-host interactions and vaccine candidates but 
its use is severely hampered by financial and ethical 
constraints
• Human-liver chimeric mice are well-characterized tools 
for the efficacy assessment of antiviral interventions
• The entry factor transgenic mouse is a recently 
developed immunocompetent mouse model, which is 
appropriate for the evaluation of both antivirals and 
murine vaccine responses
• The HIS/hep chimeric mouse combines a human liver 
with a human immune system and therefore holds 
promise to study HCV immunopathogenesis and 
resulting liver diseases. Changes to the mouse genetic 
background might further optimize human immune and 
liver cell engraftmentPreclinical in vivo models
Besides the study of natural infections that occur in humans, the
experimental infection of chimpanzees has played a pivotal role
in the discovery of HCV and has proven very valuable for
deciphering host-virus interactions and preclinical analysis ofTable 1. Overview of HCV animal models and their applicability.
HCV animal model Detectable virus 
production
Assessment of 
antiviral efficacy
Chimpanzee Persistent viraemia or 
acute self-limited
• Vaccination
• Passive immu
[136, 137] 
• Antiviral thera
[138, 139]
Tupaia Intermittent viraemia -
Viral adaptation - -
Viral protein- 
HCV transgenic mouse
- -
Genetically humanized
mouse model
No viraemia [60]
Persistent viraemia [67]
Direct: DAA [67
Indirect: Entry i
and vaccine ca
Human-liver chimeric 
mouse model
Persistent viraemia • Passive immu
[61, 85, 96, 9
• DAAs [101, 1
• Entry inhibitor
105, 106]
• Other antivira
[72, 107]
Human-liver tolerized 
rat
Viraemia (up to 16 wk) -
Human 
immunocompetent liver 
mouse model
In liver extracts -
+, reported; , not reported; n.a., not applicable.
Journal of Hepatology 201antiviral strategies [3] (Table 1). Genomes that acquired cell cul-
ture adaptive mutations were found to be highly attenuated in
chimpanzees, again underscoring the discrepancies between
these models and restrictions to the biological relevance of
in vitro systems [38]. Despite the genomic homology between
chimpanzees and humans, few chimpanzees develop chronic
HCV infection and to date no ﬁbrosis and only one hepatocellular
carcinoma (HCC) has been observed. In addition, ethical con-
straints, availability and cost are increasingly limiting the use of
these large primates for HCV research.
Although the HCV life cycle has been recapitulated in
hepatocytes derived from induced pluripotent stem cells (iPSCs)
from pigtail macaques [39], HCV does not seem to be able to
establish persistent infection in non-human primates other than
chimpanzees [40]. In addition to primates, several other species
have been evaluated for HCV susceptibility but most were resis-
tant to infection. Tree shrews (Tupaia belangeri) are non-rodent
squirrel-like mammals that were found to be permissive for
HCV infection [41]. While long-term follow-up revealed histolog-
ical progression to HCV-related liver disorders in some animals,
HCV viraemia was not sustained but could only be detected inter-
mittently. Therefore, compatibility of the Tupaia host environ-
ment with HCV replication seems rather low. Due to the
narrow host tropism of HCV, the development of small animal
models for HCV has been challenging [42]. Different approaches
have been undertaken to enable the study of the virus in a murine
environment, although mice are naturally resistant to HCV
infection. For matching a human hepatotropic pathogen with a
non-human liver, either the virus or the host must be adapted.Liver 
disease
Adaptive 
immune 
response
Availability/ 
throughput
nization 
pies 
+/- + Very low
+ - Low
- - High
+/- + High
]
nhibitors 
ndidates [60]
- + High
nization 
7]
03, 104]
s [100, 102, 
l therapies 
- - Low
+/- n.a. Low
+ + Low
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Viral adaptation
Expansion of the HCV host range could be achieved by allowing
the virus to adapt to a non-human environment. In vitro long-
term cultivation of HCV in the presence of mouse cells, or cells
expressing murine entry proteins, could familiarize the virus to
efﬁciently use such factors from this potential host (Fig. 1, left
panel). Using this approach, Bitzegeio and colleagues discovered
adaptive mutations in E1 and E2, enabling the virus to utilize
murine CD81 and OCLN for cell entry [43]. This is important
because residues in both mouse CD81 and OCLN diverging from
the human orthologs were shown to affect efﬁcient HCV infection
of mouse cells [44]. Recently, the same group reported that this
mouse adapted virus was able to infect, replicate and produce
new infectious viral particles in immortalized mouse liver cell
lines with defective innate immunity [45]. Whether this variant
needs additional adaptations for productive infection of primary
mouse hepatocytes in vivo is subject to further investigation.
Nevertheless, the applicability of such systems for the study of
entry processes might be affected by the inﬂuence of the adaptive
mutations on envelope conformation and receptor usage.
Viral protein-HCV transgenic mice
To study the in vivo interactions between the viral proteins and the
host cell, mice have been created to transgenically express these
proteins (Fig. 1 middle panel). Several investigations of transgenic
mice, containing the genetic code for HCV structural proteins E1,
and/or E2, and/or the core, or the NS3/4A protein did not provideViral adaptation Transgenic mice
Wild type HCV
In vitro adaptation
to murine entry factors
Mouse adapted HCV
Transient
adenoviral
delivery  
Oviductal
microi
fertilize
Gene expression
Wild type HCV protein
transgenic 
Entry fa
transge
Fig. 1. Different approaches to create mouse models for the study of HCV. Left panel:
variants that can establish an infection in wild type mice. Middle panel: Transient or stabl
interactions. In addition, mice can be made transgenic for human factors that are esse
models, the genetic background of the host permits repopulation of the liver upon tran
hematopoietic stem cells may result in dually reconstituted mice.
S28 Journal of Hepatology 201evidence for liver pathology [46–49]. Others, however, did
describe development of hepatic steatosis and HCC in mice upon
transgenic expression of the HCV core protein [50,51] with E1
and E2 [52]. In addition, TNF-mediated hepatic apoptosis was
affected in NS3/4A and NS5A-transgenic mice [46,53]. However,
interpretation of HCV-transgenic mouse phenotypes is compli-
cated by the random transgene integration site, its artiﬁcial
expression, the inherent immune tolerance and thepotential inﬂu-
ence of the mouse genetic background. Nevertheless, immune
tolerance can be (partially) avoided by using immune competent
mice, in which the HCV transgene expression is delayed (MUP-
promoter) [46] or inducible (using the Cre/Lox system [54] or via
hydrodynamic injection [55]). The activity of the immune system
of the MUP-HCV transgenic mice more closely resembles that of
a chronically infected patient and hence allows the evaluation of
potential therapeutic vaccine strategies [56]. Perhaps themost rel-
evant transgenic mouse model is the FL-N/35 mouse, which
expresses the complete viral polyprotein at more physiological
levels [57]. Hepatic steatosis, enhanced liver ﬁbrosis and increased
risk of HCC have been observed in this model [57–59].
The genetically humanized mouse model
Genetic manipulation of the host can be used to knock down host
factors that hamper productive HCV infection, or to complement
the host with exogenous human factors that are essential for this
process. Therefore, knowledge of the barriers that determine the
human tropism of HCV is essential. HCV uses different host
receptors for hepatocyte entry, among which CD81 and OCLNXenotransplantation
 transfer of
njected
d eggs
 fragment
Hepatocytes Hematopoietic
stem cells
Wild type HCV
ctor
nic 
Human-liver
chimeric 
Human-immune 
system/human-liver 
chimeric
Human-immune 
system chimeric
In vitro adaptation of HCV to mouse hepatoma cells may allow the isolation of viral
e expression of viral genes may provide essential information on viral protein-host
ntial to support infection of wild type HCV. Right panel: In xenotransplantation
splantation of human hepatocytes. Additional transplantation of HLA-compatible
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were identiﬁed to limit HCV mouse tropism. Indeed, both recep-
tors had to be of human origin to allow efﬁcient infection of
HCVpp in murine cells [44]. Accordingly, a genetically humanized
mouse that expresses this minimal set of human factors upon
transient adenoviral delivery supports HCV entry and allows
evaluation of entry inhibitors and vaccine candidates (Fig. 1, mid-
dle panel) [60–62]. Despite the observation that HCV RNA is
translated in mouse hepatocytes and replicons can be sustained
in murine hepatic cell lines, viral replication is not efﬁciently sup-
ported in these cells [63–65]. However, data generated with
human–mouse heterokaryon cells and murine hepatoma cells,
that ectopically express apolipoprotein E, excluded dominant
mouse factors that restricted virion assembly and egress, further
supporting the idea that a transgenic mouse model, supporting
the complete HCV life cycle, could be achieved [63,66]. More
recently Dorner and colleagues demonstrated that innate and
adaptive immune responses limited HCV replication in (four)
human entry factor-transgenic mice (4hEF) that stably express
human CD81, SR-BI, CLDN1 and OCLN [67]. Blunting the innate
immune response of 4hEF mice by crossing them with innate
immune deﬁcient mouse strains, such as STAT1 or IRF7 knockout
mice, allowed persistent infection and virus production. In these
mice viraemia disappeared after two months, most likely because
of an adaptive immune response. Since the complete HCV life
cycle is thereby recapitulated in partially immunocompetent
mice, it will be interesting to determine whether these mice
develop HCV-induced liver ﬁbrosis and/or HCC.
The human-liver xenograft mouse model
A major breakthrough in the ﬁeld was the development of human
liver xenotransplantation models. Humanization of the mouse
liver can be achieved by transplantation of primary human hepa-
tocytes into immunodeﬁcient mice that suffer from a constitutive
or inducible liver injury (Fig. 1, right panel) [37,68–72]. The
genetic immunodeﬁciency of such mice prevents xenograft rejec-
tion and the liver injury provides a competitive growth advantage
to the human donor hepatocytes over the resident mouse hepa-
tocytes. After intrasplenic injection, human hepatocytes migrate
through the portal venous system to the diseased mouse liver
where the engraftment and repopulation process is initiated. This
liver reconstitution exploits the inherent capacity of hepatocytes
to proliferate and regenerate an injured liver [73–77]. The result-
ing human-liver chimeric mouse is currently the only reproduc-
ible system that supports robust infection of non-JFH based
HCV clones and is the most widely used small animal model for
the study of HCV.
The uPA-SCID mouse with humanized liver
The regenerative capacity of individual liver cells was ﬁrst dem-
onstrated in a mouse model initially developed to study bleeding
disorders [73]. Liver dysfunction was observed in mice over-
expressing the urokinase-type plasminogen activator (uPA) trans-
gene under control of the albumin promoter. Remarkably,
hepatocytes that underwent somatic deletion of the transgene
selectively proliferated and gradually repopulated the entire liver.
Backcrossing of these mice to an immunodeﬁcient background
allowed acceptance of hepatocytes from other species [78,79].
However, in order to achieve high-level humanization of the
mouse liver, primary hepatocytes of excellent quality need to be
transplanted in mice that are homozygous for the uPA-transgeneJournal of Hepatology 201[80–82]. Mercer and colleagues were the ﬁrst to demonstrate the
susceptibility of homozygous uPA-SCID mice with human
chimeric liver to HCV infection [37]. Importantly, these mice can-
not only be infected with JFH1-based viruses, as in the cell culture
system, but also with patient-derived viruses of all genotypes
[83–85]. Although the study of host antiviral immune responses
is hampered by the immunodeﬁciency of the xenorecipient, the
chimeric uPA-SCID model has been very useful for the study of
the basic aspects of the HCV life cycle [86–95], the evaluation of
passive immunization strategies [85,96–98] and the assessment
of novel antiviral therapies [36,99–107].
The FRG mouse with humanized liver
Pre-weaning mortality, due to the transgene-induced liver dis-
ease, necessitates hepatocyte transplantation shortly after birth
in very small and fragile uPA-transgenic animals. To overcome dif-
ﬁculties in the robust generation of chimeric human-liver mice,
modiﬁcations to induce liver disease at adulthood have been
explored. An alternative xenotransplantation model that employs
such an inducible liver injury is based on a genetic knockout of
the fumarylacetoacetate hydrolase gene (FAH/), which causes
a defective tyrosine catabolic pathway, resulting in accumula-
tion of the liver toxic metabolites fumarylacetoacetate and
succinylacetone, comparable to hereditary tyrosinemia type I
[108]. Because administration of the drug 2-[2-nitro-4-(triﬂuoro-
methyl)benzoyl]cyclohexane-1,3-dione (NTBC, nitisinone) blocks
the tyrosine catabolic pathway upstream of FAH, mouse hepato-
cellular injury can be induced by NTBC withdrawal, allowing the
investigator to control the time and severity of liver disease
[108]. Extensive liver humanization was supported after crossing
FAH/ animals with recombination activating gene 2 knockout
mice (RAG2/) and IL-2 receptor c-chain knockout mice
(IL-2Rcnull), hence the designation FRG model [70,71]. Further-
more, Bissig and colleagues demonstrated productive HCV infec-
tion of these mice that was sensitive to antiviral treatment [72].
More recently, susceptibility to HCV infection was also shown
in other immunodeﬁcient liver injury models such as the MUP-
uPA [109] and HSV-TK mice [110]. Because so far no side-by-side
comparison of the different human-liver chimeric mouse models
has been performed, it is as of yet unclear how these models com-
pare to human hepatocyte or HCV biology. In any case, mice in
which the liver is extensively repopulated with primary human
hepatocytes are now increasingly being used for the study of hep-
atotropicmicroorganisms such asHBV,HCV,HDV, and Plasmodium
falciparum, the causative agent of malaria [68,111–123]; and for
the evaluation of human-type metabolism and potential toxicity
of medicinal compounds [124–129].
Immunocompetent xenograft models
One of themajor drawbacks of human-liver chimeric mousemod-
els is their requirement to be immune deﬁcient, in order to prevent
rejection of the engrafted human hepatocytes. HCV immuno-
pathogenesis, primary (human) adaptive immune response and
vaccine efﬁcacy studies in mice would require both a human liver
graft and a functional (human) immune system in one and the
same recipient animal. One attempt to overcome this hurdle was
the tolerized rat model, in which primary human hepatocytes
and HuH7 human hepatoma cells are injected into the peritoneal
cavity of foetal rats at a moment when the rat foetal immune
system is still in development [130]. Subsequent intrasplenic4 vol. 61 j S26–S33 S29
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injection of human hepatocytes or HuH7 cells one day after birth
resulted in survival of functional human cells in the absence of
rejection. This model was then explored as a platform to study
HCV infection [131]. Although HuH7-transplanted tolerized rats
were shown to produce HCV viraemia, exceeding 104 copies/ml,
no data are available on tolerized rats transplanted with primary
hepatocytes. Biochemical evidence of hepatic inﬂammation was
demonstrated by elevation of serum alanine aminotransferase
and the inﬁltration of mononuclear cells in the liver. However,
while immunocompetent, the mismatch between human HLA
and rat MHC still hampers the study of adaptive rat immune
responses against infected human hepatoma cells. Of note, the
utility of thismodel in the context of HCV infection has never been
conﬁrmed in follow-up studies by this or other groups. Because of
this mismatch between human hepatocytes and the rat immune
system, an alternative approach is to engraft mice with both
human hepatocytes and human immune cells. This has recently
been achieved by combining adult human hepatocytes and human
CD34+ hematopoietic stem cells (HSCs) from different human
donors [132]. Although the authors did not show HCV infection,
the high human engraftment levels suggest that these mice could
become viraemic when challenged with HCV. Another model was
reported by Washburn and colleagues, who generated dually
engrafted AFC8-huHSC/Hep (humanHSCs/hepatocyte progenitor)
mice after intrahepatic injection of human hepatoblasts and
CD34+ HSCs isolated from a single foetal donor (Fig. 1, right panel)
[133]. Importantly, upon viral challenge these mice developed a
demonstrable human anti-HCV T cell response and liver ﬁbrosis.
However, HCV RNA could only be detected in liver extracts and
not in the plasma of inoculated mice, possibly because of the
low level of human liver engraftment in this model. Finally,
because of the suboptimal activity of the immune system that
resides in human CD34+ HSCs transplantedmice, the utility of this
model remains to be awaited.Conclusions and future perspectives
Over the past decade different approaches have led to small HCV
animal models that can complement or replace studies in chim-
panzees. Further improvements are still needed sincemousemod-
els have thus far not exhibited the two most feared complications
of HCV infection, namely the development of liver cirrhosis and
HCC. Due to an increased understanding of key factors that deter-
mine the narrow host range of HCV, signiﬁcant progress has
recently been made in adapting the mouse environment to allow
HCV infection. Besides blunting innate immune responses in these
mice [67], additional optimisation may lead to HCV persistence
and possibly development of ﬁbrosis or HCC. In contrast to adapta-
tion of the host, the generation of host-adapted viral particles
could also overcome the species barrier. A recently described
HCV variant that is adapted for the use of murine CD81 and OCLN
for hepatocyte entry could be further adapted to resist the innate
immune response, mounted by the infected mouse hepatocyte
[43]. Separate from viral adaptation to the mouse, engraftment of
human hepatocytes in xenograftmodels has been themost widely
used model to investigate HCV in vivo [37]. Human-liver chimeric
mouse models have gradually improved with adjustments, allow-
ing the selectionof the timepoint of liver disease induction [70,72].
In addition, human liver repopulated mice have also been
transplanted together with human immune cells [133]. The possi-S30 Journal of Hepatology 201bility of combiningahuman liverwitha syngeneichuman immune
system permits the study of human adaptive immune responses
and HCV liver disease in a mouse environment. Further improve-
ments to these models will be required to enhance liver engraft-
ment levels and to overcome the limited development of human
leukocytes, particularly non-lymphocyte subsets. These models
will likely be further improved with recent advances in stem cell
and tissue engineering technologies, which in the near future
may allow for the creation of dually engrafted mice with hepato-
cyte-like cells and haematopoietic precursors, originating from
iPSCs of a single donor [134,135]. Whether such improved xeno-
graft models will develop ﬁbrosis and/or HCC remains to be deter-
mined. Therefore, even with the pending release of highly potent
direct acting antiviral treatment regimens, improved immuno-
competent animal models remain essential for the development
of an HCV vaccine and to elucidate certain clinical enigmas, e.g.,
why patients with cirrhosis require prolonged treatment or how
HCV contributes to HCC development.Financial support
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